Markets Stocks Economy Crypto Earnings Banking Energy
Home› Markets› Feature
Markets · Exclusive

Challenger rejects Daiichi Life's higher A$12.20 takeover bid

Challenger rejects Daiichi Life's higher A$12.20 takeover bid
Markets · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Nov 19, 2026 4 min read

Australian investment manager Challenger has turned down a sweetened takeover approach from Japan's Daiichi Life, saying the increased offer still does not reflect the company's fair value in a control deal. The rejection, announced after the market closed, underscores the wide gap between what the bidder is willing to pay and what the target's board believes the business is worth.

What's on the table

Daiichi Life's latest proposal values Challenger at about A$8.17 billion, according to Reuters. The offer of A$12.20 per share is aimed at the 79.5% of shares the Japanese insurer does not already own. Its local unit, TAL Dai-ichi Life Australia, already holds a 20.47% stake, according to LSEG data.

That existing stake is important. Because Daiichi already owns a fifth of the company, the higher price would only apply to the remaining shares. That means the actual cost of raising the bid is lower than the headline valuation change suggests—a factor that could give Daiichi room to sweeten its offer again without breaking the bank.

Why the board said no

The key sticking point is the premium. At A$12.20, the offer was only about 2.1% above Challenger's previous closing price. That is a modest uplift for a control transaction, where buyers typically pay a meaningful premium to secure a majority stake and take charge of a company's strategy and cash flows.

When a board rejects a bid at this stage, it often signals that the price is not close to what it considers fair value. It also means the bidder has not been granted access to detailed due diligence, a recommendation from the board, or a firm transaction timetable. Without those elements, the bid remains more of an expression of interest than a formal offer.

For investors, the rejection is a signal that the board is holding out for a better price. But it also raises the risk that Daiichi walks away, leaving Challenger's shares to trade on their own merits rather than on takeover speculation.

What it means for investors

Takeover talk can support a stock only when the bid looks credible enough to pull the share price toward it. A low control premium can do the opposite: the board can refuse to engage, and the market shifts from pricing in a deal to pricing the company as a standalone business.

That is why Challenger's shares slipped after the news. The gap between the trading price and A$12.20 now acts less like a near-certain payout and more like a live scoreboard for the chances that Daiichi materially lifts its offer. If the bidder comes back with a significantly higher price, the stock could rally. If it walks away, the shares could fall further as investors reset their expectations.

Daiichi's existing 20.47% stake also matters. It gives the Japanese insurer a seat at the table and a reason to keep pushing for a deal. But it also means that any future bid would only apply to the remaining shares, which could make a higher offer more affordable than it appears.

For now, the market is likely to treat Challenger as an active control situation rather than a normal listed manager. That means the stock's value will be driven as much by takeover speculation as by the company's underlying earnings and outlook.

The broader picture

The rejection comes at a time when M&A activity in Australia and globally is mixed. Some deals are being completed, while others are falling apart over price or financing. In a similar vein, Circle8 abandoned its takeover of SThree after financing doubts, showing how quickly deal momentum can fade.

For Challenger, the next move is up to Daiichi. The Japanese insurer could come back with a higher offer, try to negotiate directly with the board, or walk away. Investors will be watching closely for any sign of a revised bid.

In the meantime, the lesson for everyday investors is that a takeover offer is not a guaranteed payout. A low premium gives the board little reason to engage, and the stock can quickly lose its takeover premium if the deal falls through. As always, it pays to focus on the underlying business rather than the headline bid.

More from this story

Next article · Don't miss

Amer Sports sales surge 29% but stock lags; buyback signals value

Arc'teryx and Salomon owner Amer Sports is growing fast—sales up 29% this year—yet its stock is down 17%. With a $1 billion buyback and improving margins, the market may be missing the story.

Read the story →
Amer Sports sales surge 29% but stock lags; buyback signals value